Drug Trial Radar · NCT05582096
A Study of LY3457263 in Obese Participants
Last checked: Nov 19, 2026Latest source record: Jul 18, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
38
Actual
Start
Nov 11, 2022
Primary completion
Jun 8, 2023
Study completion Jun 8, 2023
Sponsor
- Lead sponsor
- Eli Lilly and CompanyEli Lilly (LLY)
- Sponsor type
- Industry
- First posted
- Oct 17, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 20 years, up to 70 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The main purpose of this study is to evaluate the safety and tolerability of LY3457263 when administered in combination with tirzepatitide in overweight or obese participants. The study will also evaluate how much of LY3457263 gets into the blood stream and how long it takes the body to remove it in overweight or obese participants. The study will last up to approximately 11 weeks.
Conditions
- Overweight
- Obesity
Interventions
LY3457263Drug
Administered SC.
TirzepatideDrug
Administered SC.
PlaceboDrug
Administered SC.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug AdministrationTime frame: Baseline up to 11 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
LabCorp CRU, Inc.
Daytona Beach, Florida
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.